Navigation Links
Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients

/p>

ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assays and in vivo animal studies have shown that binding of ERBITUX to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production. In vitro, ERBITUX can mediate antibody-dependent cellular cytotoxicity (ADCC) against certain human tumor types. While the mechanism of ERBITUX' anti-tumor effect(s) in vivo is unknown, all of these processes may contribute to the overall therapeutic effect of ERBITUX. EGFR is part of a signaling pathway that is linked to the growth and development of many human cancers, including those of the head and neck, colon and rectum.

ERBITUX (Cetuximab), in combination with radiation therapy, is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck. ERBITUX as a single agent is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed.

ERBITUX is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma (mCRC) in combination with irinotecan for patients who are refractory to irinotecan-based chemotherapy, and as a single agent for patients who are intolerant to irinotecan-based therapy. The effectiveness of ERBITUX for the treatment of EGFR-expressing mCRC cancer is based on objective response rates. Currently, no data are available that demonstrate an improvement in disease-related symptoms or increased survival with ERBITUX for the treatment of EGFR-expressing mCRC.

For full prescribing information, including boxed WARNINGS regarding infusion
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/5/2015)... 5, 2015  Adeptus Health Inc. (NYSE: ADPT ... pricing of the previously announced offering of 2,100,000 shares ... shares are to be sold by the Company, and ... of Sterling Partners (the "Selling Stockholder"), at a price ... the Company and the Selling Stockholder have granted the ...
(Date:5/5/2015)... May 5, 2015   InspireMD, Inc. (NYSE MKT: ... systems, announced today that it will release its full financial ... Monday, May 11 th before the open, followed by ... financial results and business outlook. Participants should call ... 542-4135 (International) and request the InspireMD call. A live webcast ...
(Date:5/5/2015)... , May 5, 2015 Ardelyx, ... company focused on cardio-renal, gastrointestinal, and metabolic diseases, ... trial evaluating tenapanor in Stage 3 chronic kidney ... albuminuria did not meet the primary endpoint of ... compared to patients receiving placebo. ...
Breaking Medicine Technology:Adeptus Health Inc. Announces Pricing of Common Stock Offering 2Adeptus Health Inc. Announces Pricing of Common Stock Offering 3Adeptus Health Inc. Announces Pricing of Common Stock Offering 4InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6
... CHICAGO, Nov. 18, 2010 Northwestern Memorial ... pilot study that will test whether operable lung cancer ... and better outcomes by hardwiring data systems to reduce ... standards.  The 18-month trial co-sponsored by the Commission on ...
... Nov. 18, 2010  Prism Pharmaceuticals, Inc. announced ... (FDA) has approved the supplemental new drug application ... and only premixed intravenous (IV) bag formulation of ... is indicated for initiation of treatment and prophylaxis ...
Cached Medicine Technology:Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 2Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 3Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection 2Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection 3
(Date:5/5/2015)... 2015 AxoGen, Inc. (NASDAQ: AXGN), ... $1.6 billion peripheral nerve repair market, reported record revenue ... 31, 2015 compared to $3.14 million in the year-ago ... our proprietary portfolio of nerve repair products - ... Protector – and our solid sales execution delivered another ...
(Date:5/5/2015)... The 2015 Crystal Ball, hosted by the Hepatitis ... outreach and patient advocacy programs. The gala evening included dancing, ... hundreds of supporters. , The 2015 gala was dedicated to ... virus (HBV) by Dr. Baruch S. Blumberg, who passed away ... for his discovery of the virus in 1976. He and ...
(Date:5/5/2015)... 05, 2015 Baptist Medical Center Jacksonville’s ... Cancer (CoC) of the American College of Surgeons. , ... meet more than 30 Commission on Cancer quality care ... process, and maintain levels of excellence in the delivery ... choose to seek care locally at a CoC-accredited cancer ...
(Date:5/5/2015)... " QuickPick Travel ” was featured on NewsWatch as ... small, medium, and large businesses making an impact in their ... expert, conducted the business review and shared with viewers how ... weeks of vacation for free. , Vacations are a sought-after ... world. And when people are preparing for vacations, they’re used ...
(Date:5/5/2015)... NY (PRWEB) May 05, 2015 ProTexting, ... that enables businesses to deploy Mobile Engagement Campaigns and ... Contact . ProTexting clients can now leverage the power ... by collecting and syncing subscribers’ e-mail addresses into the ... “We have recognized that the growing trend of multi-channel ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4Health News:A Platform to Plan the Perfect Vacation was Featured on NewsWatch Television 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3
... The Delhi High Court Wednesday held that the misuse of ... seriously, stressing that their services be availed of only ... and Justice S.N. Agrawal said: "No ambulance of any of ... used by the medical staff for their private use." ...
... E. McGreevy appears to be knocking on a different door. ... for the right reasons. He has been welcomed into ... James E. McGreevy, who was brought up as a Roman ... at St. Bartholomew's Church in New York. He is presently ...
... says she was upset when her pictures appeared in magazine ... all that blew up, I felt terrible. It appeared that ... am thin because that's what I am, and I was ... Nothing else," people.com quotes her as saying to a magazine. ...
... official of the United Arab Emirates (UAE) said the government ... part of the country's prevention programme of genetic disorders. ... the mother or child's health. But the choice to have ... we decide has to be within the religious and social ...
... that the malfunction of a gene causes schizophrenia and ... of the journal Neuron. ,The researchers said their ... developing treatments for schizophrenia and depression, which have been ... ,In their experiments, the researchers sought to ...
... who have migraine headaches are more than twice as likely ... than soldiers who do not have migraines, according to ... who were given a health screening questionnaire within 90 days ... A total of 2,167 of the soldiers, or 60 percent, ...
Cached Medicine News:Health News:Malfunction of Gene Causes Schizophrenia, Depression 2Health News:Migraines may Be a Symptom of Other Problems for Iraq Soldiers 2
Full plate covers seal all 24 MicroAmp tubes...
An alternative sealing method for samples that are stored in 96-well plates after PCR. The mat is fully autoclavable and can be reused up to 50 times....
Inquire...
Pkg qty: box of 2 bags pack of 25 (Pack = Zippered Bag)...
Medicine Products: